PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma.

Cell Line, Tumor Drug Resistance, Neoplasm / drug effects Humans Melanoma Protein Kinase Inhibitors / pharmacology Proto-Oncogene Proteins B-raf Signal Transduction / drug effects Skin Neoplasms Vemurafenib / pharmacology Melanoma, Cutaneous Malignant

Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
26 05 2021
Historique:
received: 07 05 2020
accepted: 19 04 2021
entrez: 27 5 2021
pubmed: 28 5 2021
medline: 30 10 2021
Statut: epublish

Résumé

BRAF inhibitors (BRAFi) selectively target oncogenic BRAF

Identifiants

DOI: 10.1038/s41598-021-89389-9 PMID: 34040017 PMC: PMC8155038
pubmed: 34040017
doi: 10.1038/s41598-021-89389-9
pii: 10.1038/s41598-021-89389-9
pmc: PMC8155038
doi:

Substances chimiques

Protein Kinase Inhibitors 0
Vemurafenib 207SMY3FQT
Proto-Oncogene Proteins B-raf EC 2.7.11.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

11023

Références

Nat Struct Mol Biol. 2013 Apr;20(4):440-6
pubmed: 23435381
N Engl J Med. 2010 Aug 26;363(9):809-19
pubmed: 20818844
N Engl J Med. 2019 Aug 15;381(7):626-636
pubmed: 31166680
Cell. 2011 Oct 14;147(2):382-95
pubmed: 22000016
Methods Mol Biol. 2014;1167:213-26
pubmed: 24823780
Melanoma Res. 2013 Dec;23(6):452-60
pubmed: 24128789
Nat Genet. 2010 May;42(5):454-8
pubmed: 20400965
Proc Natl Acad Sci U S A. 2017 Sep 12;114(37):9942-9947
pubmed: 28847966
J Invest Dermatol. 2016 May;136(5):1002-1011
pubmed: 26854490
Cancer Res. 2011 Apr 1;71(7):2750-60
pubmed: 21317224
Biomol Ther (Seoul). 2019 May 1;27(3):302-310
pubmed: 30293252
Cell Death Dis. 2017 Aug 31;8(8):e3029
pubmed: 29048432
Cell Cycle. 2014;13(2):208-19
pubmed: 24200969
Genome Biol. 2012 Sep 26;13(9):R51
pubmed: 22951037
Nature. 2010 Jun 24;465(7301):1033-8
pubmed: 20577206
Nature. 2005 Aug 4;436(7051):720-4
pubmed: 16079850
Transcription. 2010 Nov;1(3):165-175
pubmed: 21151833
Oncotarget. 2016 Jan 19;7(3):2734-53
pubmed: 26673621
Nature. 2006 Feb 16;439(7078):871-4
pubmed: 16357870
Nature. 2002 Jun 27;417(6892):949-54
pubmed: 12068308
J Invest Dermatol. 2011 Dec;131(12):2497-500
pubmed: 21833010
Nat Genet. 2009 May;41(5):544-52
pubmed: 19282848

Auteurs

Linda Vidarsdottir (L)

Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.

Alireza Azimi (A)

Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.

Ishani Das (I)

Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.

Ingibjorg Sigvaldadottir (I)

Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.

Aldwin Suryo Rahmanto (A)

Department of Cell and Molecular Biology, Karolinska Institute, Stockholm, Sweden.

Andreas Petri (A)

Center for RNA Medicine, Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark.

Sakari Kauppinen (S)

Center for RNA Medicine, Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark.

Christian Ingvar (C)

Department of Clinical Sciences, Lund University, Lund, Sweden.

Göran Jönsson (G)

Department of Clinical Sciences, Lund University, Lund, Sweden.

Håkan Olsson (H)

Department of Clinical Sciences, Lund University, Lund, Sweden.

Marianne Frostvik Stolt (M)

Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.

Rainer Tuominen (R)

Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.

Olle Sangfelt (O)

Department of Cell and Molecular Biology, Karolinska Institute, Stockholm, Sweden.

Katja Pokrovskaja Tamm (K)

Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.

Johan Hansson (J)

Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.

Dan Grandér (D)

Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.

Suzanne Egyházi Brage (S)

Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden. suzanne.egyhazi.brage@ki.se.

Per Johnsson (P)

Department of Cell and Molecular Biology, Karolinska Institute, Stockholm, Sweden. per.a.johnsson@ki.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › PTENP1-AS contributes to BRAF inhibitor...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Résistance aux médicaments antinéoplasiques › PTENP1-AS contributes to BRAF inhibitor...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › PTENP1-AS contributes to BRAF inhibitor...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Naevus et mélanomes › Mélanome › PTENP1-AS contributes to BRAF inhibitor...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de protéines kinases › PTENP1-AS contributes to BRAF inhibitor...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines oncogènes › Protéines proto-oncogènes › Kinases raf › Protéines proto-oncogènes B-raf › PTENP1-AS contributes to BRAF inhibitor...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transduction du signal › PTENP1-AS contributes to BRAF inhibitor...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Tumeurs cutanées › PTENP1-AS contributes to BRAF inhibitor...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Indoles › Vémurafénib › PTENP1-AS contributes to BRAF inhibitor...